228 related articles for article (PubMed ID: 38162494)
1. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.
Assayag J; Kim C; Chu H; Webster J
Front Oncol; 2023; 13():1194718. PubMed ID: 38162494
[TBL] [Abstract][Full Text] [Related]
2. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review.
Chen WJ; Kong DM; Li L
Asian J Androl; 2021; 23(2):163-169. PubMed ID: 33159024
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
[TBL] [Abstract][Full Text] [Related]
6. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
George DJ; Agarwal N; Sartor O; Sternberg CN; Tombal B; Saad F; Miller K; Constantinovici N; Guo H; Reeves J; Jiao X; Sandström P; Verholen F; Higano CS; Shore N
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):306-313. PubMed ID: 35190653
[TBL] [Abstract][Full Text] [Related]
7. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
Yanagisawa T; Kawada T; Rajwa P; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; König F; Pallauf M; Pradere B; Karakiewicz PI; Nyirady P; Kimura T; Egawa S; Shariat SF
Urol Oncol; 2023 Apr; 41(4):177-191. PubMed ID: 35970698
[TBL] [Abstract][Full Text] [Related]
8. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
9. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
[TBL] [Abstract][Full Text] [Related]
10. Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.
Yanagisawa T; Kawada T; Mori K; Shim SR; Mostafaei H; Sari Motlagh R; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Kimura T; Shariat SF; Rajwa P
BJU Int; 2023 Oct; 132(4):365-379. PubMed ID: 37395151
[TBL] [Abstract][Full Text] [Related]
11. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
12. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis.
Colloca G
Asia Pac J Clin Oncol; 2022 Jun; 18(3):232-239. PubMed ID: 34161667
[TBL] [Abstract][Full Text] [Related]
13. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Enei Y; Atsuta M; Mori K; Obayashi K; Yoshihara K; Kondo Y; Oguchi T; Sadakane I; Habuchi T; Ohyama C; Shariat SF; Egawa S
Prostate; 2022 Oct; 82(14):1322-1330. PubMed ID: 35767376
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data.
Maggi M; Salciccia S; Del Giudice F; Busetto GM; Falagario UG; Carrieri G; Ferro M; Porreca A; Di Pierro GB; Fasulo V; Frantellizzi V; De Vincentis G; De Berardinis E; Sciarra A
Front Oncol; 2021; 11():700258. PubMed ID: 34169003
[TBL] [Abstract][Full Text] [Related]
15. Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL; Kuppen MCP; Westgeest HM; van Moorselaar RJA; Mehra N; Coenen JLLM; van Oort IM; de Vos AI; Vervenne WL; van den Bergh ACM; Aben KKH; Somford DM; Bergman AM; Uyl-de Groot CA; Gerritsen WR; van den Eertwegh AJM
Eur Urol Focus; 2021 Jul; 7(4):788-796. PubMed ID: 32362484
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer.
Nishimoto M; Fujita K; Yamamoto Y; Hashimoto M; Adomi S; Banno E; Saito Y; Shimizu N; Mori Y; Minami T; Nozawa M; Nose K; Hirayama A; Yoshimura K; Uemura H
Transl Cancer Res; 2022 Aug; 11(8):2681-2687. PubMed ID: 36093511
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
18. Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer.
Mai L; Zhang Z; Li Y; Liu R; Li J; Huang S; Lin M; Liu B; Cao W; Wu J; Liu M; Zhou F; Liu Y; He L
Front Oncol; 2020; 10():606133. PubMed ID: 33344256
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract][Full Text] [Related]
20. Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.
Büttner T; Klümper N; Weiten R; Lossin P; Latz S; Jacobs C; Ritter M; Hauser S; Ellinger J; Krausewitz P
Prostate; 2024 May; ():. PubMed ID: 38751206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
